Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 4

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 4
---
problems. Our goal is to develop and provide new type of treatments for mental health disorders, including AUD, binge drinking and eating
disorders, where there is significant unmet need and lack of innovation. We see psychedelic therapies, which previously may have been
overlooked or underused, as the future of treatment for a variety of indications. We believe that our solution for AUD can help solve
one of the world’s biggest health problems, which costs the United States alone roughly $250 billion each year.

Our flagship treatment and
focus for the short term is on AUD, which is incredibly common. It varies from mild to excessive and describes a person’s inability
to restrict their alcohol consumption, despite negative social, occupational, or health consequences. Alcohol consumption contributes
to 3 million deaths each year globally and is the third most common preventable cause of death in the United States. In January 2025,
the U.S. Surgeon General released a new Surgeon General’s Advisory on Alcohol and Cancer Risk, outlining the direct link between
alcohol consumption and increased cancer risk, which is in addition to other common risks associated with excessive alcohol consumption.
Apart from potentially changing people’s lives, we believe that our treatment could potentially reduce the amount currently being
spent on the consequences of AUD in the United States, Europe, India, China and other countries around the world. We also believe that
our treatment may address binge drinking. 178,000 people die every year in the United States alone due to binge drinking.

We are currently focusing
our research programs on the uses of 5-Methoxy-2-aminoindane, or MEAI, for the treatment of AUD, weight loss and metabolic disorders and
as an alcohol substitute consumer products. On the consumer side, we are developing an alcohol substitute which may offer a solution that
adults can enjoy without the extensive damage that comes with alcohol, such as higher risk to get cancer and other wide range of adverse
effects on almost every part of the body, including the brain, liver, pancreas and the immune system. We have completed a series of pre-clinical,
investigational new drug—, or IND—, enabling studies in the United States and China that are required before we can study
our compound for the first time in humans. These studies include pharmacokinetic and toxicological studies in rats and dogs in order to
assess the safety profile of our compound and characterization of the drug metabolism. We have conducted several metabolism studies designed
to